

HepCup ILC EASL Congress 2025

Wed 21.05.2025, 17.30-19.30

PD Dr. David Semela (HOCH)

Benign and malignant liver tumors

Prof. Dr. Andreas Kremer, Prof. Dr. Beat Müllhaupt (USZ)

Viral hepatitis, autoimmune & cholestatic liver diseases

Prof. Dr. Annalisa Berzigotti, Dr. Susana Rodrigues (Inselspital)

Liver cirrhosis and portal hypertension

PD Dr. Nicolas Goossens (HUG)

Steatotic liver diseases

Kindly supported by:

abbvie




ZOOM Meeting-ID: 648 9891 5347

Code: 806063




Save the date

Save the date:

HepCup AASLD TLM 2025, **Wed 19.11.2025** (17.30-19.30)




Stay up to date and join the “SASL WhatsApp Channel”







- **7,742 attendees** from 119 countries, and **1,886 abstracts**
- **On-demand** content made available on **EASL Campus**. Access is limited to delegates for the first 0–3 months post-event, extended to both delegates and EASL members from 3–6 months, and open to all after 6 months.



986 pages!

<https://www.easlcongress.eu/2025-abstract-submission/>

Best of ILC slide decks: free download




Top selected abstracts from the Congress in a **downloadable and editable PowerPoint format**. These slides highlight the latest data presented at EASL Congress 2025 and are available **for your personal use**. Feel free to adapt and share them, but please **acknowledge EASL as the source**.


Link: <https://easlcampus.eu/Documents/best-easl-congress-2025-slide-decks>




EASL Clinical Practice Guidelines: 2 updated and 3 new CPGs




EASL Clinical Practice Guidelines on hepatitis B virus infection




EASL Clinical Practice Guidelines on the management of Autoimmune Hepatitis



EASL Clinical Practice Guidelines on Extrahepatic Cholangiocarcinoma



EASL Clinical Practice Guidelines on TIPS





EASL Clinical Practice Guidelines on Abdominal Extrahepatic Surgery in Patients with Cirrhosis and Advanced Chronic Liver Disease

<https://easl.eu/publication-category/clinical-practice-guidelines/>





EASL Clinical Practice Guidelines on TIPS




Consider LT evaluation in transplant candidates



EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease



EASL Clinical Practice Guidelines on on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease, J Hepatol 2025



EASL Guidelines App



Your essential app for advanced liver care




Consult EASL Clinical Practice Guidelines anytime, anywhere.



Enhance your clinical decision-making with calculators and scores.



Expand your knowledge with continuously updated resources and tools.



Explore the most recent EASL Clinical Practice Guidelines conveniently presented in a mobile-friendly format



ZOOM Meeting-ID: **648 9891 5347**

Code: **806063**

2025 EASL Community Award: Prof. Annalisa Berzigotti



GS-005: Outcomes by liver function in patients with **unresectable HCC treated with **nivolumab plus ipilimumab vs lenvatinib or sorafenib** in the CheckMate 9DW trial**


Approved systemic first line therapies for HCC in Switzerland:

Atezolizumab/Bevacizumab	(anti-PD-L1/anti-VEGF)
Durvalumab/Tremelimumab	(anti-PD-L1/anti-CTLA-4)
Sorafenib, Lenvatinib	(Tyrosine kinase inhibitors)

CheckMate 9DW trial:

Nivolumab/Ipilimumab	(anti-PD-1/anti-CTLA-4)
-----------------------------	-------------------------

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (n=668)



CheckMate 9DW trial:

Nivolumab/Ipilimumab

(anti-PD-1/anti-CTLA-4)



GS-005: Outcomes by liver function in patients with unresectable HCC treated with nivolumab plus ipilimumab vs lenvatinib or sorafenib in the CheckMate 9DW trial

Background and methods

- The phase 3 CheckMate 9DW trial recruited 668 patients with previously untreated unresectable HCC (uHCC). Patients were randomised 1:1 to received NIVO + IPI or lenvatinib or sorafenib (LEN/SOR). CHILD A 5/6.
- An Interim analysis 1L NIVO+IPI demonstrated significant OS and ORR vs LEN or SOR with durable responses and manageable safety in unresectable HCC.
- This expanded analysis evaluated efficacy and safety of NIVO + IPI vs LEN/SOR by baseline liver function status evaluated using ALBI Score.

Results

ALBI Grade


Baseline liver function evaluated using ALBI score

$$\text{ALBI Score} = (0.66 \times \log_{10}([\text{bilirubin } (\mu\text{mol/L})])) - (0.085 \times \text{albumin (g/L)})$$

ALBI	Grade 1	Grade 2*	Grade 3*
N	396	271	1

*ALBI grades 2 and 3 combined for analysis

Overall survival by ALBI grade




GS-005: Outcomes by liver function in patients with unresectable HCC treated with nivolumab plus ipilimumab vs lenvatinib or sorafenib in the CheckMate 9DW trial

Background and methods

ALBI grade 1


	NIVO + IPI (n = 186)	LEN/SOR (n = 210)
Events	90	128
Median OS, mo	35.4	23.2
95% CI	23.9-NE	21.4-28.3
HR (95% CI) ^a	0.75 (0.57-0.98)	



No. at risk	0	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48	51
NIVO + IPI	186	174	158	144	134	130	113	103	97	92	70	48	27	14	6	5	0	0
LEN/SOR	210	201	187	169	152	139	126	110	86	78	60	36	27	15	2	2	0	0

ALBI grade 2/3

	NIVO + IPI (n = 149)	LEN/SOR (n = 123)
Events	104	100
Median OS, mo	16.9	14.0
95% CI	12.6-23.0	11.1-16.6
HR (95% CI) ^a	0.75 (0.57-0.99)	



No. at risk	0	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48	51
NIVO + IPI	149	126	106	95	86	76	66	59	53	45	34	23	15	10	5	3	0	0
LEN/SOR	123	109	93	76	64	55	38	34	30	28	16	8	7	5	2	1	1	0

GS-005: Outcomes by liver function in patients with unresectable HCC treated with nivolumab plus ipilimumab vs lenvatinib or sorafenib in the CheckMate 9DW trial

Background and methods

- The phase 3 CheckMate 9DW trial recruited 668 patients with previously untreated unresectable HCC (uHCC). Patients were randomised 1:1 to received NIVO + IPI or lenvatinib or sorafenib (LEN/SOR). CHILD A 5/6.
- An Interim analysis 1L NIVO+IPI demonstrated significant OS and ORR vs LEN or SOR with durable responses and manageable safety in unresectable HCC.
- This expanded analysis evaluated efficacy and safety of NIVO + IPI vs LEN/SOR by baseline liver function status evaluated using ALBI Score.

Results

ALBI Grade


Baseline liver function evaluated using ALBI score

$$\text{ALBI Score} = (0.66 \times \log_{10}([\text{bilirubin } (\mu\text{mol/L})])) - (0.085 \times \text{albumin (g/L)})$$

ALBI	Grade 1	Grade 2*	Grade 3*
N	396	271	1

*ALBI grades 2 and 3 combined for analysis

Overall survival by ALBI grade



NIVO + IPI showed clinically meaningful OS improvement with higher 24- and 36-month OS rates vs LEN/SOR, regardless of ALBI grade.

GS-005: Outcomes by liver function in patients with unresectable HCC treated with nivolumab plus ipilimumab vs lenvatinib or sorafenib in the CheckMate 9DW trial

Results (cont.)

TRAEs by ALBI grade

All treated patients, n (%)	ALBI grade 1				ALBI grade 2/3			
	NIVO + IPI (n = 186)		LEN/SOR (n = 205)		NIVO + IPI (n = 146)		LEN/SOR (n = 120)	
	Any grade	Grade 3/4	Any grade	Grade 3/4	Any grade	Grade 3/4	Any grade	Grade 3/4
TRAEs^a								
Any TRAEs	156 (84)	78 (42)	188 (92)	87 (42)	122 (84)	59 (40)	109 (92)	51 (43)
AST increased	36 (19)	9 (5)	16 (8)	0	29 (20)	11 (8)	11 (9)	2 (2)
ALT increased	35 (19)	10 (5)	12 (6)	1 (< 1)	28 (19)	6 (4)	7 (6)	2 (2)
Serious TRAEs	57 (31)	47 (25)	26 (13)	24 (12)	37 (25)	36 (25)	21 (18)	18 (15)
TRAEs leading to discontinuation	37 (20)	27 (15)	19 (9)	12 (6)	22 (15)	17 (12)	15 (13)	9 (8)
Treatment-related deaths^b	6 (3) ^c		1 (< 1) ^d		6 (4) ^e		2 (2) ^f	

Conclusions



- **NIVO + IPI efficacy** vs LEN/SOR was **consistent across ALBI subgroups**.
- **Safety**, including hepatic safety, was **comparable across ALBI subgroups**.
- NIVO + IPI showed a **favourable benefit-risk profile** across ALBI grades.
- These results support **NIVO + IPI as a 1L treatment option for uHCC**, regardless of baseline liver function.

GS-005: Outcomes by liver function in patients with **unresectable HCC treated with **nivolumab plus ipilimumab vs lenvatinib or sorafenib** in the CheckMate 9DW trial**

Approved systemic first line therapies for HCC in Switzerland:

Atezolizumab/Bevacizumab	(anti-PD-L1/anti-VEGF)
Durvalumab/Tremelimumab	(anti-PD-L1/anti-CTLA-4)
Nivolumab/Ipilimumab	(anti-PD-1/anti-CTLA-4)
Sorafenib, Lenvatinib	(Tyrosine kinase inhibitors)

EASL Clinical Practice Guidelines on the Management of HCC





SASL School of Hepatology 48

June 16th, 2025, 17.30-19.00



HCC: What's New in the 2025 EASL Guidelines
Prof. Dr. Bruno Sangro (Pamplona)



Wilson's Disease: Diagnostics & Therapy
Dr. Isabelle Mohr (Heidelberg)

Transplant Oncology Symposium


June 21st 2025, University Hospital Zurich, Grosser Hörsaal OST B 10

Department of Visceral and Transplant Surgery
Department of Gastroenterology & Hepatology
Department of Medical Oncology and Hematology

Transplant Oncology Symposium

Saturday, 21st June 2025
09.00-14.40

University Hospital Zurich, Rämistrasse 100, 8091 Zürich – Grosser Hörsaal OST B 10



Program

- 09.00-09.20** **Welcome Remarks by the Chair**
José Oberholzer, University Hospital Zurich, Visceral and Transplant Surgery
- 09.20-09.40** **Transplant Oncology – Current Status in Switzerland**
Pascale Tinguely, University Hospital Zurich, Visceral and Transplant Surgery
- 09.40-10.00** **Liver Transplantation for HCC**
Henrik Petrowsky, University Hospital Zurich, Visceral and Transplant Surgery
- 10.00-10.20** **Advances in the Multidisciplinary Management of HCC**
Andreas Kremer, University Hospital Zurich, Gastroenterology & Hepatology
- 10.20-10.40** **Liver Transplantation for Biliary Tracts Cancers (Online)**
Gregory J. Gores, Mayo Clinic, Rochester, Minnesota, Gastroenterology and Hepatology
- 10.40-11.00** **Neoadjuvant and Adjuvant Treatment for Transplant-eligible BTCs**
TBC –
- 11.00-11.15** **Coffee Break**
- 11.15-11.35** **Liver Transplantation for Colorectal Liver Metastasis**
TBC - Pål-Dag Line, Oslo University Hospital, Transplantation Medicine
- 11.35-11.55** **Liver Transplantation for NET**
TBC - Vincenzo Mazzaferro, Università degli Studi di Milano, Oncology and Hematology-Oncology
- 11.55-12.15** **Liver Transplant for Metastatic Disease – The Oncologist’s Perspective**
Ralph Fritsch, University Hospital Zurich, Medical Oncology and Hematology
- 12.15-13.00** **Lunch Break**
- 13.00-13.20** **Living Donor Liver Transplantation in Transplant Oncology**
Nico Goldaracena, UVA Health Transplant Center, Surgery & Transplant Surgery
- 13.20-13.40** **Living Donor – Ethical Aspects**
Tanja Krones, University Hospital Zurich, Clinical Ethics
- 13.40-14.00** **The role of Machine Perfusion in the Transplant Oncology Era**
Stefan Schneeberger, University Hospital for Visceral, Transplantation and Thoracic Surgery Innsbruck
- 14.00-14.20** **Immunosuppression in Transplant Oncology – Adaptions When and How?**
TBC – Fabrizio Di Benedetto, Università degli Studi di Modena e Reggio Emilia, Department for Surgery
- 14.20-14.40** **Discussion / Closing Remarks**
Andreas Kremer, University Hospital Zurich, Gastroenterology & Hepatology

Endorsed by



1st Swiss Rare Liver Disease Symposium, 4th June 2025, Bern



1st Swiss Rare Liver Disease Symposium

CHALLENGES IN THE MANAGEMENT OF RARE LIVER DISEASES

„Bringing together leading experts from research, clinics, and diverse medical fields, this congress aims to foster collaboration and advance our understanding of fibrosis across organ systems—driving innovation toward better treatments and patient outcomes.“

Bern, Switzerland
Wednesday, June 4th 2025

Venue:

Building UniS, Lecture Hall S003,
Schanzeneckstrasse 1, 3012 Bern

Organised by:

Swiss Rare Liver & Swiss Association
for the Study of the Liver (SASL)



12:00 - 12:30	Welcome bites
12:30 – 12.40	Introduction and opening remarks (Valérie McLin / Andreas Kremer)
12.40 – 14.00	Session 1: Who we are and what we do (moderators: Nicolas Goossens, Valérie McLin)
12.40 – 13.00	Presentation of the Swiss Rare Liver (Valérie McLin)
13.00 – 13.30	Current ongoing registries in Switzerland (Andreas Cerny, Andrea De Gottardi, Montserrat Fraga, Andreas Kremer, Valérie McLin)
13.30 – 14.00	Patient organisations in Switzerland (Swiss HePa, Wilson, Alpha-1, Hepa Family, Mahana)
14.00 – 14.15	Bio Break
14:15 – 15:30	Session 2: Cholestatic liver disease (moderators: Nathalie Rock, Vasiliki Spyropoulou)
14.15 – 14.45	Diagnostic criteria and aims of treatment including IBATs in adults and children (Ekkehard Sturm)
14.45 – 15.05	Novel PPARs: efficacy and safety (Andreas Kremer)
15.05 – 15.20	Floor discussion
15:20 – 15:50	Coffee Break
15.50 – 16.45	Session 3: Autoimmune hepatitis (moderators: Andrea De Gottardi, Anja Lachenmayer)
15.50 – 16.10	Pathophysiology and therapeutic targets of AIH (Benedetta Terziroli)
16.10 – 16.30	Diagnostic criteria and treatment goals in children (Christiane Sokollik)
16.30 – 16.45	Floor discussion
16.45 – 17.00	Bio Break
17:00 – 18:15	Session 4: Challenges (moderators: Annalisa Berzigotti, Magdalena Filipowicz, David Semela)
17.00 – 17.20	Novel insights and current treatments in HDV (Montserrat Fraga)
17.20 – 17.50	Lessons learnt from treating children and adults with Wilson's disease (Dominique Debray)
17.50 – 18.15	Floor discussion: Unmet needs



We thank the sponsors for their generous support of this
HepCup webinar



GILEAD

abbvie